Gerald Nabozny
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gerald Nabozny.
Journal of Clinical Investigation | 1997
David Bradley; Gerald Nabozny; Shen Cheng; Paul Zhou; Marie M. Griffiths; Harvinder S. Luthra; Chella S. David
Certain HLA-DR alleles have been associated with predisposition to human rheumatoid arthritis (RA). There is also evidence that certain HLA-DQ alleles may also be important in determining susceptibility to RA. We have previously demonstrated that mice transgenic for HLA-DQ8, a DQ allele associated with susceptibility to RA, develop severe arthritis after type II collagen immunization. To investigate the influence of polymorphic difference at the DQ loci on susceptibility to arthritis, we generated mice transgenic for HLA-DQ6, an allele associated with a nonsusceptible haplotype. The DQ6 mice were found to be resistant to collagen-induced arthritis. We also assessed the combined effect of an RA-susceptible and an RA nonassociated DQ allele by producing double-transgenic mice expressing DQ6 and DQ8 molecules, representing the more prevalent condition found in humans where heterozygosity at the DQ allele is common. The double-transgenic mice developed moderate CIA when immunized with CII when compared with the severe arthritis observed in DQ8 transgenic mice, much like RA patients bearing both susceptible and nonsusceptible HLA haplotypes. These studies support a role for HLA-DQ polymorphism in human RA.
Journal of Clinical Investigation | 1999
Svetlana P. Chapoval; Gerald Nabozny; Eric V. Marietta; Ernie L. Raymond; Christopher J. Krco; Amy G. Andrews; Chella S. David
The human leukocyte antigen (HLA) restriction of the IgE response to different allergens in humans has been a subject of numerous published studies. However, the role and contribution of specific HLA class II molecules in the pathogenesis of allergic airway inflammation are unknown and difficult to assess. HLA-DQ6 and HLA-DQ8 transgenic mice lacking endogenous mouse class II gene expression were actively immunized and later challenged intranasally with short ragweed (SRW) allergenic extract. The HLA-DQ transgenic mice developed pulmonary eosinophilia and lung tissue damage. We also found an increase in total protein (TP) level and IL-5 production in bronchoalveolar lavage (BAL) fluid and an increase in SRW-specific Th2-type immunoglobulins (IgG1, IgG2b) and total serum IgE levels. Under similar treatment, DQ-negative full-sib control mice were normal. The allergic response could be significantly inhibited or abrogated in HLA-DQ mice by systemic treatment with anti-DQ mAb. The in vivo responses of HLA-DQ6 and HLA-DQ8 mice showed differences in terms of levels of eosinophilia, BAL protein, IL-5 concentration, and lung hyperreactivity to inhaled methacholine. These findings demonstrate the crucial role for specific HLA-DQ molecules in SRW-specific CD4(+) T-cell activation and resulting recruitment of eosinophils into the airways.
Cell Reports | 2014
Heeseog Kang; Audrey Kerloc’h; Maxime Rotival; Xiaoqing Xu; Qing Zhang; Zelpha D’Souza; Michael Kim; Jodi A Carlson Scholz; Jeong-Hun Ko; Prashant K. Srivastava; Jonathan R. Genzen; Weiguo Cui; Timothy J. Aitman; James E. Melvin; Adedayo Hanidu; Janice Dimock; Jie Zheng; Donald Souza; Aruna K. Behera; Gerald Nabozny; H. Terence Cook; J. H. Duncan Bassett; Graham R. Williams; Jun Li; Agnès Vignery; Enrico Petretto; Jacques Behmoaras
Summary Macrophages can fuse to form osteoclasts in bone or multinucleate giant cells (MGCs) as part of the immune response. We use a systems genetics approach in rat macrophages to unravel their genetic determinants of multinucleation and investigate their role in both bone homeostasis and inflammatory disease. We identify a trans-regulated gene network associated with macrophage multinucleation and Kcnn4 as being the most significantly trans-regulated gene in the network and induced at the onset of fusion. Kcnn4 is required for osteoclast and MGC formation in rodents and humans. Genetic deletion of Kcnn4 reduces macrophage multinucleation through modulation of Ca2+ signaling, increases bone mass, and improves clinical outcome in arthritis. Pharmacological blockade of Kcnn4 reduces experimental glomerulonephritis. Our data implicate Kcnn4 in macrophage multinucleation, identifying it as a potential therapeutic target for inhibition of bone resorption and chronic inflammation.
Bioorganic & Medicinal Chemistry Letters | 2006
Hidenori Takahashi; Younes Bekkali; Alison Capolino; Thomas A. Gilmore; Susan E. Goldrick; Paul Kaplita; Lisa Liu; Richard M. Nelson; Donna Terenzio; Ji Wang; Ljiljana Zuvela-Jelaska; John R. Proudfoot; Gerald Nabozny; David S. Thomson
We have recently reported the discovery of a novel class of glucocorticoid receptor (GR) antagonists, exemplified by 3, containing a 1,2-dihydroquinoline molecular scaffold. Further SAR studies of these antagonists uncovered chemical modifications conveying agonist functional activity to this series. These agonists exhibit good GR binding affinity and are selective against other nuclear hormone receptors.
Immunity | 2017
Kyuho Kang; Sung Ho Park; Janice Chen; Yu Qiao; Eugenia G. Giannopoulou; Karen Berg; Adedayo Hanidu; Jun Li; Gerald Nabozny; Keunsoo Kang; Kyung-Hyun Park-Min; Lionel B. Ivashkiv
&NA; Mechanisms by which interferon (IFN)‐&ggr; activates genes to promote macrophage activation are well studied, but little is known about mechanisms and functions of IFN‐&ggr;‐mediated gene repression. We used an integrated transcriptomic and epigenomic approach to analyze chromatin accessibility, histone modifications, transcription‐factor binding, and gene expression in IFN‐&ggr;‐primed human macrophages. IFN‐&ggr; suppressed basal expression of genes corresponding to an “M2”‐like homeostatic and reparative phenotype. IFN‐&ggr; repressed genes by suppressing the function of enhancers enriched for binding by transcription factor MAF. Mechanistically, IFN‐&ggr; disassembled a subset of enhancers by inducing coordinate suppression of binding by MAF, lineage‐determining transcription factors, and chromatin accessibility. Genes associated with MAF‐binding enhancers were suppressed in macrophages isolated from rheumatoid‐arthritis patients, revealing a disease‐associated signature of IFN‐&ggr;‐mediated repression. These results identify enhancer inactivation and disassembly as a mechanism of IFN‐&ggr;‐mediated gene repression and reveal that MAF regulates the macrophage enhancer landscape and is suppressed by IFN‐&ggr; to augment macrophage activation. Graphical Abstract Figure. No caption available. HighlightsIFN‐&ggr; suppresses basal expression of M2‐like genes in human macrophagesIFN‐&ggr; downregulates MAF and targets MAF‐binding enhancers for suppressionA subset of IFN‐&ggr;‐inactivated enhancers loses TF binding and chromatin accessibilityLow MAF expression correlates with a “negative IFN‐&ggr; signature” in RA macrophages &NA; Kang et al. demonstrate that IFN‐&ggr; represses basal expression of M2‐like genes by targeting enhancers. IFN‐&ggr; induces loss of enhancer binding by MAF and lineage‐determining transcription factors, with concomitant “disassembly” and loss of chromatin accessibility. These results provide new insights into how IFN‐&ggr; regulates gene expression and activates macrophages.
Bioorganic & Medicinal Chemistry Letters | 2011
Raj Betageri; Thomas A. Gilmore; Daniel Kuzmich; Thomas M. Kirrane; Jörg Bentzien; Dieter Wiedenmayer; Younes Bekkali; John R. Regan; Angela Berry; Bachir Latli; Alison Kukulka; Tazmeen N. Fadra; Richard M. Nelson; Susan E. Goldrick; Ljiljana Zuvela-Jelaska; Don Souza; Josephine Pelletier; Roger M. Dinallo; Mark Panzenbeck; Carol Torcellini; Heewon Lee; Edward Pack; Christian Harcken; Gerald Nabozny; David S. Thomson
We report a SAR of non-steroidal glucocorticoid mimetics that utilize indoles as A-ring mimetics. Detailed SAR is discussed with a focus on improving PR and MR selectivity, GR agonism, and in vitro dissociation profile. SAR analysis led to compound (R)-33 which showed high PR and MR selectivity, potent agonist activity, and reduced transactivation activity in the MMTV and aromatase assays. The compound is equipotent to prednisolone in the LPS-TNF model of inflammation. In mouse CIA, at 30 mg/kg compound (R)-33 inhibited disease progression with an efficacy similar to the 3 mg/kg dose of prednisolone.
Journal of Pharmacological and Toxicological Methods | 2011
Suzanne Nodop Mazurek; Jun Li; Gerald Nabozny; Glenn A. Reinhart; Akalushi Muthukumarana; Paul C. Harrison; Ryan M. Fryer
INTRODUCTION Long-term administration of non-selective matrix metalloproteinase (MMP) inhibitors, such as marimastat, in humans elicits musculoskeletal syndrome (MSS), a syndrome characterized by joint damage including pain, stiffness, and inflammation. This pathology is a significant obstacle to the clinical development of MMP inhibitors and in pre-clinical models MSS can be verified only after terminal histopathology. Consequently, we devised a longitudinal and functional readout of MSS in conscious rats treated with marimastat that was validated against terminal histological assessment. METHODS MSS was induced by minipump infusion of marimastat (5-10mg/kg/day). In marimastat-treated or vehicle-control groups, three possible functional biomarkers were assessed: paw volume (PV), landing foot splay separation (LFSS), and rotarod performance (n=6 rats/group for each endpoint). RESULTS Histologically, fibrosis scores in the synovium and ligament increased from 0 on Day 1 (D1) to 4.6±0.2 and 4.7±0.1, respectively, on D15; growth plate thickness was also elevated from 215.0±6.3μm (D1) to 253.3±8.0μm (D15). While neither PV nor LFSS were correlative with MSS histopathology, marimastat (10mg/kg/day) reduced rotarod performance from 180±0s (D0) to 135±30s (D9) using a constant speed protocol (10rpm, 180s) and from 180±0s (D0) to 96±6s (D6) employing a variable speed protocol (increasing from 5 to 25rpm over 180s). DISCUSSION Results of the present study demonstrate that rotarod performance can be used as a predictive longitudinal, in vivo functional biomarker of MSS concomitant with histological evidence of joint damage to effectively facilitate compound selection during drug discovery. Moreover, for targets with a mechanistic risk for MSS, the model is also conducive to inclusion in secondary pharmacodynamic studies during lead optimization to identify the best (safest) compounds for advancement into clinical trials.
Bioorganic & Medicinal Chemistry Letters | 2014
Hossein Razavi; Doris Riether; Christian Harcken; Jörg Bentzien; Roger M. Dinallo; Donald Souza; Richard M. Nelson; Alison Kukulka; Tazmeen Fadra-Khan; Edward J. Pack; Ljiljana Zuvela-Jelaska; Josephine Pelletier; Mark Panzenbeck; Carol Torcellini; John R. Proudfoot; Gerald Nabozny; David S. Thomson
Synthesis and structure-activity relationship (SAR) of a series of alkyl and cycloalkyl containing non-steroidal dissociated glucocorticoid receptor (GR) agonists is reported. This series of compounds was identified as part of an effort to replace the CF3 group in a scaffold represented by 1a. The study culminated in the identification of compound 14, a t-butyl containing derivative, which has shown potent activity for GR, selectivity against the progesterone receptor (PR) and the mineralocorticoid receptor (MR), in vitro anti-inflammatory activity in an IL-6 transrepression assay, and dissociation in a MMTV transactivation counter-screen. In a collagen-induced arthritis mouse model, 14 displayed prednisolone-like efficacy, and lower impact on body fat and free fatty acids than prednisolone at an equivalent anti-inflammatory dose.
European Journal of Pharmacology | 2001
Raymond J. Winquist; Sudha Desai; Stephen Fogal; Nancy Haynes; Gerald Nabozny; Patricia L. Reilly; Donald Souza; Maret Panzenbeck
Both preclinical and clinical data have identified leukocyte function-associated antigen-1 (LFA-1) as an important component of inflammatory disease states. We evaluated small molecule inhibitors of this glycoprotein in several animal models in which the inflammatory process is dependent on human or non-human primate LFA-1. (R)-5(4-bromobenzyl)-3(3,5-dichlorophenyl)-1,5-dimethylimidazolidine-2,4-dione, BIRT 377, effectively suppressed the production of human immunoglobulin (IgG) following reconstitution of severe combined immunodeficient (SCID) mice with human peripheral blood mononuclear cells. The BIRT 377 analog, BIX 642, inhibited the cellular infiltrate and increase in skin thickness associated with the delayed-type hypersensitivity reaction in previously immunized squirrel monkeys challenged with antigen. BIX 642 also inhibited the trans-vivo delayed-type hypersensitivity response in the footpads of SCID mice injected with human peripheral blood mononuclear cells and donor-sensitive antigen. These results demonstrate the efficacy of small molecule inhibitors of LFA-1 in preclinical models of inflammation dependent on human or non-human primate LFA-1.
Scientific Reports | 2015
P. Edward Purdue; Tania N. Crotti; Zhenxin Shen; Jennifer Swantek; Jun Li; Jonathan Hill; Adedayo Hanidu; Janice Dimock; Gerald Nabozny; Steven R. Goldring; Kevin P. McHugh
As the only cells capable of efficiently resorbing bone, osteoclasts are central mediators of both normal bone remodeling and pathologies associates with excessive bone resorption. However, despite the clear evidence of interplay between osteoclasts and the bone surface in vivo, the role of the bone substrate in regulating osteoclast differentiation and activation at a molecular level has not been fully defined. Here, we present the first comprehensive expression profiles of osteoclasts differentiated on authentic resorbable bone substrates. This analysis has identified numerous critical pathways coordinately regulated by osteoclastogenic cytokines and bone substrate, including the transition from proliferation to differentiation, and sphingosine-1-phosphate signaling. Whilst, as expected, much of this program is dependent upon integrin beta 3, the pre-eminent mediator of osteoclast-bone interaction, a surprisingly significant portion of the bone substrate regulated expression signature is independent of this receptor. Together, these findings identify an important hitherto underappreciated role for bone substrate in osteoclastogenesis.